This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Joseph Menzin, PhD; Kathleen Lang, PhD; Craig C. Earle, MD; Donna Kerney, PhD; Rajiv Mallick, PhD

Arch Intern Med. 2002;162:1597-1603.

Background  The incidence of acute myeloid leukemia (AML) among the elderly can be expected to grow as the population continues to age. However, data on current treatment practices and costs for this form of cancer are sparse.

Methods  We used a retrospective inception cohort design and data from a linkage between 11 Surveillance, Epidemiology, and End Results cancer registries and Medicare administrative claims. We evaluated survival, use of health care resources, use of chemotherapy, and Medicare payments among adults 65 years and older with an initial diagnosis of AML between January 1, 1991, and December 31, 1996.

Results  A total of 2657 elderly patients with AML and complete Medicare claims data were identified. The prognosis for these patients was poor, with median survival estimated to be 2 months and a 2-year survival rate of 6%. Mean ± SE total Medicare payments were $41 594 ± $870 (in 1998 US dollars), 84% of which was attributed to inpatient payments. In the 2 years after the AML diagnosis, 790 patients (30%) underwent chemotherapy treatment. These patients had costs almost 3 times higher than those of other patients, and their median survival was 6 months longer. The use of hospice care was rare (17% of patients).

Conclusions  Among the elderly, AML is associated with a poor prognosis and substantial costs during the relatively few remaining months of life. Moreover, most patients do not receive active treatment with chemotherapy or hospice services. Further work is needed to characterize this disease and the patient-related factors that influence treatment decisions and associated health outcomes.

From Boston Health Economics, Inc, Waltham, Mass (Drs Menzin, Lang, and Kerney); the Dana-Farber Cancer Institute, Boston, Mass (Dr Earle); and Wyeth-Ayerst Research, Collegeville, Pa (Dr Mallick).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Case 28-2009 -- A 68-Year-Old Man with Fatigue, Cough, and Peripheral-Blood Monocytosis
Dey et al.
NEJM 2009;361:1099-1106.
FULL TEXT  

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Harousseau et al.
Blood 2009;114:1166-1173.
ABSTRACT | FULL TEXT  

Withdrawing Medically Futile Treatment
Howard and Pawlik
J Oncol Pract 2009;5:193-195.
FULL TEXT  

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Juliusson et al.
Blood 2009;113:4179-4187.
ABSTRACT | FULL TEXT  

Acute Myelogenous Leukemia in Older Adults
Klepin and Balducci
The Oncologist 2009;14:222-232.
ABSTRACT | FULL TEXT  

Acute Appendicitis in Young Children: Cost-effectiveness of US versus CT in Diagnosis--A Markov Decision Analytic Model
Wan et al.
Radiology 2009;250:378-386.
ABSTRACT | FULL TEXT  

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
Gardin et al.
Blood 2007;109:5129-5135.
ABSTRACT | FULL TEXT  

Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
Giles et al.
JCO 2007;25:25-31.
ABSTRACT | FULL TEXT  

Prognostic Factors in Elderly Patients with AML and the Implications for Treatment
Erba
ASH Education Book 2007;2007:420-428.
ABSTRACT | FULL TEXT  

Adult Acute Myeloid Leukemia
Jabbour et al.
Mayo Clin Proc. 2006;81:247-260.
ABSTRACT | FULL TEXT  

CLORETAZINETM (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).
Giles et al.
ASH ANNUAL MEETING ABSTRACTS 2005;106:2786-2786.
ABSTRACT  

Comorbid Disease and Cancer: The Need for More Relevant Conceptual Models in Health Services Research
Geraci et al.
JCO 2005;23:7399-7404.
FULL TEXT  

Trends in Outcomes and Charges of Acute Myeloid Leukemia in the Elderly: A Cross-Sectional Analysis of the Nationwide Inpatient Sample from 1993 to 2001.
Katz et al.
ASH ANNUAL MEETING ABSTRACTS 2004;104:3142-3142.
ABSTRACT  

Acute Myeloid Leukemia in the Elderly: Longitudinal Outcomes and Hospital Charges in Chemotherapy and Non-Chemotherapy Patients.
Katz et al.
ASH ANNUAL MEETING ABSTRACTS 2004;104:3154-3154.
ABSTRACT  

The Economic Cost of Squamous Cell Cancer of the Head and Neck: Findings From Linked SEER-Medicare Data
Lang et al.
Arch Otolaryngol Head Neck Surg 2004;130:1269-1275.
ABSTRACT | FULL TEXT  

Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity
Bountioukos et al.
Eur J Echocardiogr 2003;4:300-305.
ABSTRACT | FULL TEXT